<DOC>
	<DOCNO>NCT01059084</DOCNO>
	<brief_summary>The purpose study look effect daily herpes medication , valacyclovir , HIV level blood person HIV positive oral genital herpes .</brief_summary>
	<brief_title>An Open-label Trial Effect Valacyclovir Plasma HIV-1 Levels Among HIV-1 Seropositive HSV-1/2 Seronegative Persons</brief_title>
	<detailed_description>The purpose study look effect daily herpes medication , valacyclovir HIV level blood person genital herpes . This help well understand effect valacyclovir play spread HIV potential role HIV treatment decrease HIV spread . A total 20 individual HIV-1 seropositive HSV-1/2 seronegative recruit study . Participants must antiretroviral therapy must plan initiate HIV antiretroviral therapy study . Participants ask come clinic total 16 visit course 10 week . Participants receive valacyclovir 1000 mg three time daily 6 week . During first week , participant return clinic total 2 visit provide plasma sample baseline HIV-1 level . During second week , participant return clinic total 5 visit . At Visit 3 , participant provide study medication . After drug initiation , participant ask return clinic within 6 hour Day 1 , 2 , 3 post first dose . During week 3-8 , participant instruct take valacyclovir return clinic one follow-up visit week provide plasma sample HIV-1 detection . Participants ask return clinic 3 follow-up visit study drug discontinuation provide plasma sample HIV-1 detection . Participants ask complete daily symptom medication diary . All supply study medical provide . This outpatient study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>&gt; 18 year old HIV1 seropositive CD4 count &gt; 250 cell/mm3 Detectable HIV1 plasma viral load HSV1 &amp; 2 seronegative . Not HIV antiretroviral therapy planning initiate antiretroviral therapy study period . Not intend move area duration study participation Willing able provide independent write informed consent . Willing able undergo clinical evaluation . Willing able take study drug direct . Willing able adhere followup schedule Known history adverse reaction acyclovir , valacyclovir , famciclovir . Use ganciclovir , foscarnet , cidofovir History evidence CMV disease Known medical history seizure Known renal insufficiency , define serum creatine &gt; 1.5 mg/dl AST ALT &gt; 3times upper limit normal Hematocrit &lt; 30 % Neutropenia , define absolute neutrophil count &lt; 1000 Thrombocytopenia , define platelet count &lt; 75,000 History thrombotic microangiopathy For woman , pregnancy confirm urine pregnancy test Any condition , opinion principal investigator , may compromise ability follow study procedure complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>Valacyclovir</keyword>
	<keyword>ValtrexÂ®</keyword>
</DOC>